[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Lin CC, Hsu CH, Pu YS: Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: a two-case study. Anticancer Res; 2006 Jul-Aug;26(4B):3191-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: a two-case study.
  • BACKGROUND: The risk of urothelial carcinoma (UC) is increased in patients with end-stage renal disease.
  • Standard regimens for UC (e.g., M-VAC) carry substantial toxicity, which could be exacerbated in patients with end-stage renal disease receiving kidney transplantation, because of the need to take immunosuppressants for life.
  • PATIENTS AND METHODS: Patients who had metastatic UC, and normal bone marrow, liver and kidney functions, were eligible.
  • Concomitant immunosuppressants were maintained during chemotherapy.
  • RESULTS: From 2003 to 2004, two female renal allograft recipients developed renal pelvis UC with para-aortic and lung metastasis, respectively.
  • The patients remained disease-free for 2 and 1 year, respectively, after completion of the chemotherapy.
  • CONCLUSION: The TP-HDFL regimen showed activity and can be safely used in renal allograft recipients with metastatic UC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Transplantation. Urologic Neoplasms / drug therapy. Urologic Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886656.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Murakami T, Komiya A, Mikata K, Kaneko S, Ikeda I: Cardiac metastasis of renal pelvic cancer. Int J Urol; 2007 Mar;14(3):240-1
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastasis of renal pelvic cancer.
  • Seven months previously he had undergone a laparoscopic left nephroureterectomy for a left renal pelvic tumor and was given two cycles of adjuvant chemotherapy (methotrexate, epirubicin and cisplatin).
  • On computed tomography, multiple lung tumors, as well as the right atrial and ventricular mass, were seen.
  • On autopsy, a right atrial and ventricular metastasis of the initial transitional cell carcinoma was found.
  • The patient's cause of death was acute heart failure as a result of cardiac metastasis of his initial renal pelvic carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Heart Neoplasms / secondary. Kidney Neoplasms / pathology. Kidney Pelvis
  • [MeSH-minor] Aged. Diagnosis, Differential. Echocardiography. Fatal Outcome. Humans. Laparoscopy. Male. Nephrectomy / methods. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430263.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


3. Hoshi S, Shintaku I, Suzuki K, Takahashi T, Kaihou Y, Ishidoya S, Namima T, Ohyama C, Orikasa S: Bladder preservation by internal iliac arterial infusion chemotherapy and irradiation in T3 bladder carcinoma patients over the age of 70 years. Tohoku J Exp Med; 2000 Dec;192(4):249-58
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder preservation by internal iliac arterial infusion chemotherapy and irradiation in T3 bladder carcinoma patients over the age of 70 years.
  • Treatment by internal iliac arterial infusion chemotherapy (IA) combined with pelvic irradiation has proved to be effective for locally invasive bladder.
  • Three to 7 cycles of cisplatin (CDDP) 30-50 mg/m2, methotrexate 20 mg/m2 and tetrahydropymnyl-adriamycin 20 mg/m2 every 3 week was administered combined with 40-50 Gy. of whole pelvis irradiation.
  • In 4 renal function impaired patients, 100 mg/m2 of carboplatin was administered instead of CDDP.
  • One N2 patient died with metastatic disease and two died without carcinoma.
  • Two patients developed invasive bladder cancer on the side opposite to the primary tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Health Services for the Aged / utilization. Methotrexate / therapeutic use. Urinary Bladder / physiology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11286315.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Chen ZF, Zheng SB, Wu P, Zhang P, Jiang YD, Zhao SC, Mao XM, Chen ZR, Shan ZF: [Synchronous squamous cell carcinoma of the renal pelvis and squamous cell carcinoma of the ureter: report of two cases and review of literature]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec;30(12):2765-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous squamous cell carcinoma of the renal pelvis and squamous cell carcinoma of the ureter: report of two cases and review of literature].
  • OBJECTIVE: To study the clinicopathological characteristics of synchronous squamous cell carcinoma (SCC) of the renal pelvis and SCC of the ureter.
  • METHODS: The clinical data of two cases of synchronous SCC of the renal pelvis and SCC of the ureter were retrospectively reviewed and analyzed.
  • In case 1, a 68-year-old man with hematuria for a month, imaging modalities revealed a right renal pelvis tumor and a right distal ureter tumor.
  • Case 2, a 60-year-old man with the complaint of lower abdominal pain and left flank pain for a month, was diagnosed as left distal ureteral stone in another hospital.
  • The pathological report demonstrated SCC, and the patient was transferred to our hospital for further treatment.
  • We found a left renal mass invading the left hemicolon during surgery, and nephroureterectomy was performed with a bladder cuff excision, left hemicolon resection, and also complete lymph node dissection.
  • Neither of patients received adjuvant radiotherapy/chemotherapy.
  • RESULTS: Moderately differentiated SCC was reported in both of renal pelvis and ureter in case 1 and the tumor invaded the subepithelial connective tissue in the renal pelvis and superficial muscle in the ureter.
  • In case 2, moderately differentiated SCC of the left renal pelvis with colon metastasis and poorly differentiated SCC of the ureter was reported with two retroperitoneal lymph node metastases.
  • The two patients died from tumor recurrence and metastasis 5 and 6 months after the surgery, respectively.
  • CONCLUSION: Synchronous SCC of the renal pelvis and SCC of the ureter are rare and has high likeliness of early recurrence and metastasis, often with poor prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Kidney Neoplasms / complications. Kidney Pelvis. Ureteral Neoplasms / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21177201.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


5. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol; 2004 Oct;172(4 Pt 1):1271-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
  • The role of adjuvant radiation therapy and chemotherapy is not well defined.
  • We retrospectively reviewed the records of 31 patients who underwent surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy to determine overall outcome as well as impact of concurrent chemotherapy administration.
  • MATERIALS AND METHODS: Between 1970 and 1997, 31 patients with nonmetastatic transitional cell carcinoma of the upper urinary tract (renal pelvis in 13, ureter in 15, and renal pelvis and ureter in 3) were treated with radiotherapy following attempted curative resection.
  • The median radiation dose was 46.9 Gy.
  • Nine patients received methotrexate, cisplatin and vinblastine chemotherapy for 2 to 4 cycles, followed by concurrent cisplatin with radiation.
  • Seven patients (23%) experienced locoregional failure with distant metastases developing in all except 1 within 8 months of locoregional failure diagnosis.
  • Five-year actuarial overall survival, disease specific survival, locoregional control and metastasis-free survival rates were 39%, 52%, 67% and 48%, respectively.
  • On univariate analysis patients had improved 5-year actuarial overall and disease specific survival with the administration of concurrent chemotherapy (27% vs 67%, p = 0.01 and 41% vs 76%, p = 0.06, respectively).
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Pelvis. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / radiotherapy
  • [MeSH-minor] Actuarial Analysis. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Outcome and Process Assessment (Health Care). Radiation-Sensitizing Agents / therapeutic use. Radiotherapy, Adjuvant. Survival Rate. Ureter / pathology. Ureter / surgery


6. Watanabe M, Hayashi T, Takamatsu M, Kamitani A, Inoue M, Morisue K, Irie S, Kaneshige T: [A clinical study of renal pelvic and ureteral cancer: prognosis and frequency of subsequent bladder cancer following surgical treatment]. Nihon Hinyokika Gakkai Zasshi; 2003 Mar;94(3):428-33
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of renal pelvic and ureteral cancer: prognosis and frequency of subsequent bladder cancer following surgical treatment].
  • PURPOSE: A retrospective investigation of patients presenting with renal pelvic and ureteral cancer was performed.
  • This study focused on the prognostic factors and frequency of subsequent bladder cancer following surgical treatment.
  • Seventeen patients exhibited renal pelvic cancer, 25 cases displayed ureteral cancer and three subjects presented with multiple cancers.
  • Eleven patients had received treatment for precedent or coexistent superficial bladder cancer by transurethral resection.
  • Ten patients died as a result of the disease; in all cases, lymph node or distant metastasis had progressed.
  • CONCLUSIONS: Adjuvant chemotherapy for prevention of clinical metastasis should be considered in cases involving pT3 or higher stage, grade 3, or in instances of pathologically confirmed lymph node metastasis.
  • The significant occurrence of subsequent bladder cancer in the case of tumor multiplicity suggested that prophylactic therapy such as intravesical BCG instillation or chemotherapy might be beneficial.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / etiology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Postoperative Period. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12710077.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Helke C, May M, Hoschke B: [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function]. Aktuelle Urol; 2006 Sep;37(5):363-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
  • [Transliterated title] Gemcitabine/Carboplatin-Chemotherapie in der Behandlung des metastasierten Urothelkarzinoms unter besonderer Berücksichtigung von Patienten mit eingeschränkter Nierenfunktion.
  • PURPOSE: The aim of this analysis is the evaluation of the activity and toxicity of gemcitabine and carboplatin in patients with advanced urothelial transitional carcinoma (TCC) with special regard to patients with impaired renal function.
  • PATIENTS AND METHODS: 30 consecutive patients with metastatic TCC [mean age: 68 (range: 47 - 82) years, median ECOG-PS:1] were treated with gemcitabine (1000 mg/m (2) on days 1 and 8 of a 21-day schedule) and carboplatin (AUC 4.5 day 1).
  • In 15 patients (considered as renal unfit) a creatinine clearance of less than 60 mL/min (range: 31 - 59 mL/min) was seen.
  • RESULTS: Concerning the survival rate, no significant difference noticed between the two subgroups of renal impaired patients and patients with normal renal function was detected (median 13 vs. 14 months, p = 0.901).
  • Median time to progression was 5.34 months.
  • There was no restriction of renal function under chemotherapy in any single patient.
  • CONCLUSIONS: The chemotherapy combination of gemcitabine and carboplatin is definitely powerful for a first-line-therapy in patients with advanced TCC.
  • Decreases of effectiveness in cases of impaired renal function were not detected.
  • Patients with metastatic TCC should be entered onto well designed, randomised clinical trials with the gemcitabine/carboplatin combination to afford a tailored chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Failure, Chronic / complications. Kidney Function Tests. Ureteral Neoplasms / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Kidney Pelvis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Metastasis / pathology. Prospective Studies. Survival Rate. Ureter / pathology. Urinary Bladder / pathology


8. Chung SD, Wang SM, Lai MK, Huang CY, Liao CH, Huang KH, Pu YS, Chueh SC, Yu HJ: Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. BJU Int; 2009 Apr;103(8):1047-51
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy.
  • OBJECTIVE: To evaluate the significance of lymphovascular invasion (LVI) to predict cancer-specific survival (CSS) in patients with renal pelvic urothelial carcinoma (UC).
  • PATIENTS AND METHODS: In all, 76 patients with primary renal pelvic UC were treated by nephroureterectomy (NU).
  • Inclusion criteria included nonmetastatic renal pelvic UC with no previous history of bladder cancer, concomitant ureteric lesion, or neoadjuvant chemotherapy.
  • CONCLUSIONS: Adrenal metastases from primary renal pelvic UCs were rare.
  • The present results suggest that ipsilateral adrenalectomy is not necessary during radical NU for treating patients with renal pelvic UCs.
  • LVI appears to be a better prognostic factor for predicting poor outcome of renal pelvic UC than pT stage or tumour grade when using the current tumour-nodes-metastases staging system.
  • [MeSH-minor] Adrenalectomy / mortality. Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2009 Apr;103(8):1143 [19338572.001]
  • (PMID = 19076143.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Zhang Y, Gu ZY, Tian Z, Yang C, Cai XY: Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case. Int J Oral Maxillofac Surg; 2010 Jul;39(7):737-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case.
  • Transitional cell carcinoma of the renal pelvis is initially a slow growing tumor arising from the transitional epithelium of the mucous membrane of the renal pelvis.
  • The common metastasis is in the lung, liver, brain and bone.
  • Oral metastasis is seldom reported.
  • The authors report an unusual case of transitional cell carcinoma of the renal pelvis metastasized to the oral cavity and lung simultaneously in a 74-year-old man, which occurred 1 year after a left nephroureterectomy.
  • The patient underwent six courses of chemotherapy (gemcitabine, oxaliplatin, fluorouracil and nedaplatin), and received radiotherapy for the oral lesion.
  • Repeated radiotherapy for oral metastasis was performed, but the patient died 4 years after the initial nephroureterectomy due to multiple metastases.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Mouth Neoplasms / secondary
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fatal Outcome. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Nephrectomy. Radiotherapy, Adjuvant. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20236801.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


10. Matsuda R, Motoyama Y, Takeshima Y, Kimura R, Iida J, Nakamura M, Mishima H, Park YS, Hirabayashi H, Nakase H, Sakai T: [A case of brain metastasis of renal pelvic carcinoma]. No Shinkei Geka; 2009 Feb;37(2):179-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis of renal pelvic carcinoma].
  • Contrast-enhanced computed tomography (CT) revealed renal tumor and multiple lung metastases.
  • After nephroureterectomy, combination chemotherapy consisting of methotrexate, doxorubicin and cisplatin was performed.
  • Pathological examination indicated transitional cell carcinoma the same feature as in the renal pelvis.
  • Repeated surgical resection and stereotactic radiosurgery was performed, but she died 44 months after the initial nephroureterectomy due to the relapse of brain metastasis.
  • Brain metastasis of renal pelvic carcinoma is extremely rare, and we have found only three case reports.
  • We describe the course of our patient, and review the three cases of brain metastasis of renal pelvic carcinoma that are in the literature.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227160.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


11. Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW: [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases]. Rofo; 2007 Nov;179(11):1174-80
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases].
  • [Transliterated title] Transarterielle Chemoperfusion des Beckens--Ergebnisse bei symptomatischen Rezidivtumoren und Lymphknotenmetastasen.
  • PURPOSE: To evaluate local transarterial chemoperfusion (TACP) of therapy-resistant, locally recurrent malignant tumors and lymph node metastases in the pelvis with respect to clinical response, tumor response and survival.
  • In the case of clinical and radiological progression, therapy was stopped and the patient was referred to the hospital's tumor board.
  • In the case of radiological response and clinical progression or clinical response and radiological progression, therapy was continued.
  • Therapy could be stopped by the patient at any time.
  • RESULTS: Treatment was tolerated well by all patients.
  • Tumor response (median survival since first TACP) was as follows: colorectal: 2 PR, 7 SD, 2 PD (11.5 months), ovarian: 1 SD, 2 PD (8.5 mon), cervical: 1 PR, 1 SD (6 mon), breast: 2 SD (6 mon), gastric: 1 PD (11 mon), adrenal gland: 1 PD (12 mon), anal: 1 PD (10 mon), prostate: 1 PD (20 mon), Gartner's duct: 1 PR (20 mon), renal cell carcinoma: 1 SD (10 mon).
  • CONCLUSION: Since tumor-related complaints were improved in 54% of the cases and control of tumor growth (PR+SD) was achieved in 67% of the cases, TACP for recurrent pelvic malignancies should be considered as a palliative oncological treatment option.
  • [MeSH-major] Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arteries. Drug Resistance, Neoplasm. Female. Humans. Injections, Intra-Arterial / adverse effects. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Perfusion / adverse effects. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805998.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


12. Okada T, Tsukazaki H, Itoh M, Nishio Y, Muro H: [Renal pelvic cancer representing G-CSF production and hypercalcemia simultaneously: a case report]. Hinyokika Kiyo; 2002 Mar;48(3):155-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal pelvic cancer representing G-CSF production and hypercalcemia simultaneously: a case report].
  • Abdominal ultrasonography and computed tomography revealed a left renal tumor with extracapsular extension.
  • Laboratory data showed marked leukocytosis of 121,000/mm3 and hypercalcemia of 12.3 mg/dl without any findings of inflammatory disease or bone metastasis.
  • Pathological diagnosis of needle biopsy specimen of the primary tumor was transitional cell carcinoma which was suspected to have originated from renal pelvis.
  • The patient underwent a course of systemic chemotherapy, but died two months after diagnosis.
  • To our knowledge, this is the first report of renal pelvic cancer representing granulocyte colony-stimulating factor production and hypercalcemia simultaneously.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Granulocyte Colony-Stimulating Factor / biosynthesis. Hypercalcemia / complications. Kidney Neoplasms / metabolism. Kidney Pelvis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11993209.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 21
  •  go-up   go-down


13. Gakis G, Merseburger AS, Sotlar K, Kuczyk MA, Sievert KD, Stenzl A: Metastasis of malignant melanoma in the ureter: possible algorithms for a therapeutic approach. Int J Urol; 2009 Apr;16(4):407-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of malignant melanoma in the ureter: possible algorithms for a therapeutic approach.
  • We report on the very rare case of a patient with a malignant melanoma in the right ureter initially hospitalized for colic pains.
  • Histomorphological and immunohistochemical examination of the biopsy specimen demonstrated a malignant neoplasia with HMB45, Melan A and S100 positivity establishing the diagnosis of metastatic malignant melanoma.
  • Hence, partial ureterectomy was performed with no further evidence of disease at the time of surgical intervention.
  • Subsequently, multiple metastases in the renal pelvis and ureter led to secondary nephroureterectomy and retroperitoneal lymphadenectomy with complete excision of the ureteral orifice.
  • Secondary metastatic lesions of the urinary bladder wall were completely resected followed by dacarbazine-based chemotherapy and resection of retroperitoneal recurrences.
  • Based on this case as well as on recent published reports, we propose a possible algorithm for the treatment of metastatic melanoma of the upper urinary tract.
  • [MeSH-major] Algorithms. Melanoma / secondary. Melanoma / therapy. Skin Neoplasms / pathology. Ureteral Neoplasms / secondary. Ureteral Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416402.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


14. Weizer AZ, Faerber GJ, Wolf JS Jr: Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma. Urology; 2007 Sep;70(3):469-72
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite rigorous surveillance, we have identified 3 patients with renal parenchymal recurrences and/or metastatic disease without progression of renal pelvis disease.
  • METHODS: Three patients with renal parenchymal and/or metastatic UC were identified through routine clinical care.
  • Indications were solitary kidney in 2 patients and renal insufficiency in 1 patient.
  • Despite apparently successful management for 9 to 50 months, with complete tumor resection on initial and subsequent treatments, and at least 1 tumor-free period was documented in 2 of the 3 patients, parenchymal recurrence, metastases, or both were confirmed in 1 patient each.
  • One patient underwent nephroureterectomy and the other 2 patients received adjuvant chemotherapy.
  • CONCLUSIONS: Despite complete initial resection of upper tract disease and apparent successful surveillance, these 3 patients had renal parenchymal recurrence and/or metastatic disease without obvious progression of collecting system disease.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology. Ureteroscopy
  • [MeSH-minor] Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Electrocoagulation. Humans. Kidney Pelvis / pathology. Lymphatic Metastasis. Male. Nephrectomy / methods. Paclitaxel / administration & dosage. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905098.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Makino H, Kametaka H, Koyama T, Seike K: [A case of unresectable advanced gallbladder cancer successfully treated by a combined administration of gemcitabine + CDDP]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2714-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • His history included resections of the left kidney and ureter due to a cancer of the left renal pelvis.
  • The diagnosis was gallbladder cancer with infiltration of the liver and mesoduodenal ligament and lymphatic metastasis.
  • But his condition was judged not to be amenable to surgery: the procedure was limited to an exploratory laparotomy.
  • Chemotherapy composed of gemcitabine 1,000 mg/m2 + CDDP 25 mg/m2 (administered for 2 weeks followed by one week of no treatment, repeated for 8 cycles) was initiated on the 16th day of illness.
  • In a phase III trial (the UK ABC-02 trial) conducted by the American Society of Clinical Oncology (ASCO) in 2009, in which gemcitabine + CDDP combination therapy was compared against gemcitabine monotherapy to treat patients with advanced or metastatic biliary tract cancers, the overall duration of survival was significantly prolonged and the mortality risk reduced.
  • After one cycle applied while the patient was in the hospital, no adverse effects of the chemotherapy were found and a subsequent treatment was given on an outpatient basis.
  • No adverse effects attributable to the chemotherapy were noted until 8 cycles were completed.
  • With a careful observation of the clinical course, the procedure for unresectable gallbladder cancer shown here may be applied on an outpatient basis.
  • It is an effective and safe therapeutic modality, which may become a standard therapeutic procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224689.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y: Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int; 2010 Sep;106(5):658-63
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma.
  • OBJECTIVE: To investigate the role of (18) F-fluorodeoxyglusose positron-emission tomography (FDG-PET), combined with computed tomography (CT) and forced diuresis, in the staging and follow-up of urothelial carcinoma (UC).
  • PATIENTS AND METHODS: We recruited 44 patients with muscle-invasive urothelial bladder cancer (UBC) before radical cystectomy (RC), 19 under follow-up after RC and seven after systemic chemotherapy.
  • For those who had RC, histopathology was used as the reference standard to compare the sensitivity and specificity of FDG-PET/CT and standard CT in detecting UBC and pelvic lymph node metastasis.
  • RESULTS: For the detection of primary UBC, FDG-PET/CT was slightly more sensitive than CT (85% vs 77%) but less specific (25% vs 50%).
  • For the detection of pelvic node metastasis FDG-PET/CT was more sensitive than CT (57% vs 33%) with a specificity of 100% for both imaging techniques.
  • FDG-PET/CT also detected a pT1G3 UC of the renal pelvis and all bone metastases detected by bone scintigraphy.
  • CONCLUSIONS: FDG-PET/CT could replace standard CT and bone scintigraphy in the presurgical staging and monitoring of patients with UC after surgery or chemotherapy.
  • [MeSH-major] Lymph Nodes / pathology. Positron-Emission Tomography / standards. Tomography, X-Ray Computed / methods. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cystectomy. Epidemiologic Methods. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging / methods. Prognosis. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.
  • (PMID = 20151968.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T: Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol; 2003 Jun;169(6):2072-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Although laparoscopy is being increasingly used to treat urological malignancies, there is still concern regarding the induction of local recurrence and port site metastasis.
  • We assessed the oncological safety of laparoscopy with emphasis on incidence of local recurrence and port site metastasis, analyzing the risk factors for such events based on a 10-year experience.
  • There were recurrences after nephroureterectomy for transitional cell carcinoma of the ureter in 1 patient, after radical nephrectomy for renal cell carcinoma in 1, growing teratoma after retroperitoneal lymph node dissection in 2, local recurrence of prostate cancer in 3 and after removal of an adrenal metastasis of melanoma in 1.
  • Two port site metastases (0.18% overall, 0.35% of histologically proved cases) occurred, including metastasis of small cell lung carcinoma after adrenalectomy and a residual mass following 2 cycles of chemotherapy after retroperitoneal lymph node dissection.
  • [MeSH-minor] Adrenalectomy. Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Seeding. Nephrectomy. Pelvis. Postoperative Complications. Prostatectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771722.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Wu N, Liu Y, Lin D, Chen Y, Shi M: [Abdominal and pelvic lymph nodes in non-Hodgkin lymphoma: the nodal distribution in Chinese patients]. Zhonghua Zhong Liu Za Zhi; 2002 Nov;24(6):580-4
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3. Treated patients who did not have abdominal and/or pelvic CT before, showed regression of initial disease for at lease 6 months after chemotherapy and patients showing abdominal and/or pelvic nodal lesions (n = 8) were assessed.
  • These were predominantly seen superior and inferior to the renal hila, with incidences of 72.0% (18/25) in IL and 67.3% (33/49) in AL.
  • The involved retroperitoneal lymph nodes are predominantly located superior and inferior to the renal hila.
  • [MeSH-major] Abdomen. Lymph Nodes. Lymphoma, Non-Hodgkin / pathology. Pelvis
  • [MeSH-minor] Adolescent. Adult. Aged. Asian Continental Ancestry Group. Child. China / epidemiology. Female. Humans. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12667330.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Mekki M, Belghith M, Krichène I, Zakhama A, Landolsi A, Chelly S, Nouri A: [Fetal rhabomyomatous nephroblastoma. Report of 2 cases and review of the literature]. Ann Urol (Paris); 2002 Jul;36(4):245-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Le néphroblastome rhabdomyomateux foetal. A propos de deux cas et revue de la littérature.
  • The aim of this work is to study the principal clinic, therapeutic and evolutive characteristics of the fetal rhabdomyomatous nephroblastoma through two personal cases and a review of the literature.
  • The diagnosis was confirmed in the two cases by the histologic examination.
  • The radiologic and biologic explorations load, in the two cases, to the diagnosis of left nephroblastoma.
  • After a first chemotherapy that did not induce a reduction of the tumoral volume, a widened left nephrectomy was performed for the two patients.
  • The histologic examination of the two pieces of nephrectomy concluded to a fetal rhabdomyomatous nephroblastoma with existence in the second case of an extension of the lesions to the renal pelvis and ureter in the form of a pseudo-botryoïde tumor.
  • The treatment was completed by an adapted post operative chemotherapy according to the SIOP 9 protocol.
  • CONCLUSION: The fetal rhabdomyomatous nephroblastoma is a special histologic form of nephroblastoma that is characterized by the paucity of pulmonary metastasis, the absence of response to chemotherapy and the possibility of tumoral extension in the renal pelvis and ureter.
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant. Kidney / pathology. Male. Nephrectomy. Prognosis. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12162188.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Firat S, Murray K, Erickson B: High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):201-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
  • PURPOSE: To evaluate the role of high-dose whole abdominal and pelvic irradiation (WART) in the treatment of epithelial ovarian carcinoma.
  • None of the patients had received chemotherapy before RT.
  • Thirty-one patients received Alkeran or cyclophosphamide and two received cisplatin-based chemotherapy after WART.
  • The median whole abdominal dose was 36 Gy (range 9-45.5), delivered in a median of 30 fractions (range 8-46).
  • The median pelvic dose was 51 Gy (range 16-59).
  • The right lobe and a portion of the left lobe of the liver were shielded with custom blocks at a median dose of 25 Gy (range 9-41).
  • The median dose to the kidneys was 19 Gy (range 4-30).
  • For this group, a total abdominal dose of > or /=36 Gy was associated with a longer overall survival independent of stage, grade, and the amount of residual disease.
  • This was most likely due to a significant reduction in the incidence of abdominal recurrence in patients receiving >36 Gy to the whole abdomen (18% vs. 49%, p = 0.006).
  • Twenty-one percent (n = 15) of the patients developed Grade 3 or 4 (Radiation Therapy Oncology Group [RTOG] criteria) chronic small or large bowel toxicity.
  • A whole abdominal dose >30 Gy and a pelvic dose >50 Gy were associated with a significant increase in small bowel obstruction (p = 0.01) independent of other factors.
  • Grade 3 or 4 renal toxicity (RTOG) was observed in 4%, and 2 patients (3%) were diagnosed with pelvic insufficiency fractures that were managed conservatively.
  • CONCLUSION: Survival after RT for ovarian carcinoma rivals that achieved with systemic chemotherapy.
  • Careful attention to balancing toxicity and efficacy is imperative if RT is to have a future role in the treatment of this disease.
  • [MeSH-major] Neoplasm Recurrence, Local / mortality. Ovarian Neoplasms / mortality. Ovarian Neoplasms / radiotherapy
  • [MeSH-minor] Abdomen / radiation effects. Adult. Aged. Dose-Response Relationship, Radiation. Female. Humans. Longitudinal Studies. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pelvis / radiation effects. Prognosis. Radiation Injuries / etiology. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909234.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


21. Roger N, Zafrani Y, Uzan C, Gouy S, Rey A, Pautier P, Lhommé C, Duvillard P, Castaigne D, Morice P: Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer? Ann Surg Oncol; 2008 Jan;15(1):333-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) a complete pelvic and bilateral para-aortic lymphadenectomy up to the level of the left renal vein;.
  • (3) surgical procedures including lymphadenectomies performed before adjuvant chemotherapy; and (4) a description of the distribution of positive nodes removed between pelvic and para-aortic areas.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Lymph Node Excision. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aorta. Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Para-Aortic Bodies. Pelvis. Prognosis. Retrospective Studies


22. Mirza IA, Shahab N: Small cell cancer of the pleura, kidney, and thymus. Semin Oncol; 2007 Feb;34(1):67-9
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell carcinoma of the kidney and renal pelvis is rare.
  • Although nephrectomy has been used for treatment it does not appear to confer any significant benefit.
  • Cisplatin-based chemotherapy has improved the median survival from 8 months to 20 months.
  • Surgery, radiation, and chemotherapy have been used in the management of these tumors with variable results.
  • [MeSH-minor] Humans. Neoplasm Metastasis. Prognosis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270669.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


23. Garcia del Muro X, Marcuello E, Gumá J, Paz-Ares L, Climent MA, Carles J, Parra MS, Tisaire JL, Maroto P, Germá JR: Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer; 2002 Feb 1;86(3):326-30
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy in patients with urothelial cancer.
  • Thirty-eight patients with locally advanced or metastatic transitional-cell carcinoma of the bladder, renal pelvis or ureter received the combination of docetaxel 75 mg m(-2) and cisplatin 75 mg m(-2) on day 1 and repeated every 21 days, to a maximum of six cycles.
  • The median delivered dose-intensity was 98% (range 79-102%) of the planned dose for both drugs.
  • The median time to progression was 6.9 months, and the median overall survival was 10.4 months.
  • There was one toxic death in a patient with grade 4 granulocytopenia who developed acute abdomen.
  • Docetaxel plus cisplatin is an effective and well-tolerated regimen for the treatment of advanced urothelial cancer, and warrants further investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Paclitaxel / analogs & derivatives. Taxoids. Urologic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Time Factors. Treatment Outcome. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology. Urothelium

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 The Cancer Research Campaign
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2546-52 [10561321.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] Ann Oncol. 1999 Nov;10(11):1385-8 [10631471.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1461-5 [10643537.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):840-6 [10673526.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1058-61 [10694557.001]
  • [Cites] Eur J Cancer. 2000 Jan;36(1):74-9 [10741298.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1921-7 [10784633.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2537-44 [10893284.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3247-55 [10986057.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1612-6 [11104554.001]
  • [Cites] J Urol. 2001 Jan;165(1):67-71 [11125366.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2527-33 [11331332.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2448-58 [2819654.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1078-9 [8683639.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1655-9 [8932351.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1071-9 [9060547.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1853-7 [9164195.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):255-60 [9440750.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1844-8 [9586899.001]
  • [Cites] Urology. 1998 Jul;52(1):56-60 [9671871.001]
  • [Cites] Br J Cancer. 1998 Aug;78(3):370-4 [9703285.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2722-7 [9704723.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3392-7 [9779718.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1342-5 [9823976.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2876-81 [10561365.001]
  • (PMID = 11875692.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2375206
  •  go-up   go-down


24. Deffieux X, Morice P, Thoury A, Camatte S, Duvillard P, Castaigne D: Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma. J Am Coll Surg; 2005 Jan;200(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Between 1985 and 2003, 19 women with primary fallopian tube carcinoma underwent systematic bilateral pelvic and para-aortic lymphadenectomy up to the level of the left renal vein.
  • Initial lymphadenectomy (without chemotherapy) was performed in 6 patients and in 13 patients lymphadenectomies were performed after chemotherapy at the time of second-look operation.
  • Lymphadenectomy should involve all pelvic and para-aortic chains up to the level of the left renal vein, even in patients with stage I disease.
  • [MeSH-major] Carcinoma / secondary. Fallopian Tube Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aorta, Abdominal. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Pelvis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15631919.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Takeshita S, Ichida H, Kayama A, Sugiura A, Umezawa K, Yokoyama S, Sugiura S, Shimizu Y, Machida R, Miyazaki Y, Arimura K, Satoh T, Ryo E, Ayabe T: [Concurrent chemoradiation therapy for advanced cervical cancer]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1443-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiation therapy for advanced cervical cancer].
  • In 2003, we began a clinical application of concurrent chemoradiation therapy (CCR) in patients with cervical cancer in our hospital.
  • Patients received radiation therapy (50 Gy of external beam radiotherapy for pelvis and 20 Gy of high-dose rate intracavitary brachytherapy) combined with chemotherapy.
  • Cisplatin was administered intravenously every 3 weeks at a dose of 70 mg/m(2) during the radiation therapy.
  • One case developed acute renal failure and another suffered intolerable exhaustion.
  • There was no statistical difference in the overall survival between CCR and radiation therapy alone.
  • The CCR response rate in patients with paraaortic lymph node swelling (suspected metastasis) was low, and they had a poor prognosis.
  • [MeSH-major] Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy / adverse effects. Female. Humans. Lymph Nodes / pathology. Middle Aged. Prognosis


26. Verbeek W, Schulten HJ, Sperling M, Tiesmeier J, Stoop H, Dinjens W, Looijenga L, Wörmann B, Füzesi L, Donhuijsen K: Rectal adenocarcinoma with choriocarcinomatous differentiation: clinical and genetic aspects. Hum Pathol; 2004 Nov;35(11):1427-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor showed an aggressive clinical behavior with metastasis to the liver and lungs.
  • A transient partial remission was achieved after 4 cycles of cisplatinum, etoposide, and ifosfamide chemotherapy, with normalization of serum beta-human chorionic gonadotropin levels.
  • At this time, viable residual choriocarcinoma cells were found in surgically resected lung metastasis.
  • The patient succumbed 8 months after initial diagnosis to a rapid abdominal relapse.
  • We used comparative genomic hybridization (CGH) and fluorescence in situ hybridization to elucidate the genetic relationship of adenocarcinoma and choriocarcinoma in this neoplasm.
  • In contrast to findings from a comparative study on a choriocarcinoma of the renal pelvis, we did not find an amplification of the germ cell cancer-associated chromosomal region 12p11.2-p12.1 in the areas of choriocarcinoma but found instead a loss of Xp11.3-pter.
  • [MeSH-major] Adenocarcinoma / secondary. Cell Transformation, Neoplastic. Choriocarcinoma, Non-gestational / secondary. Neoplasms, Multiple Primary / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. DNA, Neoplasm / analysis. Fatal Outcome. Female. Humans. Hysterectomy. In Situ Hybridization, Fluorescence. Middle Aged. Nucleic Acid Hybridization. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668903.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


27. McClay EF, McClay ME, Monroe L, Baron PL, Cole DJ, O'Brien PH, Metcalf JS, Maize JC: The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br J Cancer; 2000 Jul;83(1):16-21
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
  • The adjuvant treatment of high-risk malignant melanoma remains problematic.
  • Previously we reported moderate success in the treatment of metastatic disease using tamoxifen, cisplatin, dacarbazine and carmustine.
  • During the first 2 years of follow-up, patients were evaluated every 2 months with a history, physical exam, laboratory work and computed tomography scans of the chest, abdomen and pelvis every 4 months.
  • No effect of gender or number of positive lymph nodes was noted, however, stage of disease prior treatment was a factor.
  • Minimal renal, haematologic and neurologic toxicity occurred.
  • These preliminary results suggest that there is a positive impact of tamoxifen and cisplatin on both the DFS and OS of high-risk malignant melanoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antiemetics / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Dexamethasone / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Granisetron / therapeutic use. Humans. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Nausea / chemically induced. Nausea / prevention & control. Neoplasm Metastasis. Neoplasm Staging. Ondansetron / therapeutic use. Prognosis. Risk. Survival Analysis. Tamoxifen / administration & dosage. Tamoxifen / adverse effects. Treatment Outcome. Vomiting / chemically induced. Vomiting / prevention & control

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904 [2593166.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1292-5 [2920358.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):736-40 [2016616.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):427-9 [1728371.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):553-6 [1537621.001]
  • [Cites] N Engl J Med. 1992 Aug 20;327(8):516-23 [1635566.001]
  • [Cites] Ann Plast Surg. 1992 Jan;28(1):65-9 [1642409.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6790-6 [1458467.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1571-6 [8453625.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1237-42 [8343260.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1914-8 [8364868.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):1018-22 [8253520.001]
  • [Cites] Am J Clin Oncol. 1994 Feb;17(1):55-9 [8311008.001]
  • [Cites] Lancet. 1994 Apr 9;343(8902):913-4 [7908370.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2119-30 [8156517.001]
  • [Cites] Br J Cancer. 1994 Sep;70(3):449-52 [8080729.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2776-83 [7595738.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):7-17 [8558223.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8 [8703684.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2083-90 [8683240.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2666-73 [8874325.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1425-9 [9552047.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1884-90 [10561229.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1403-5 [6541973.001]
  • [Cites] Cancer Treat Rep. 1987 May;71(5):465-9 [3567970.001]
  • [CommentIn] Br J Cancer. 2000 Jul;83(1):6-7 [10883660.001]
  • (PMID = 10883662.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA52151
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 0 / Antiemetics; 094ZI81Y45 / Tamoxifen; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; WZG3J2MCOL / Granisetron
  • [Other-IDs] NLM/ PMC2374536
  •  go-up   go-down






Advertisement